| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.007 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.09 | 0.008 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.089 | 0.008 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.009 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.009 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |